Sruamsiri Rosarin, Kaneko Yuko, Mahlich Jörg
Health Economics, Janssen Pharmaceutical KK, 5-2, Nishi-kanda 3-chome Chiyoda-ku, Tokyo, 101-0065 Japan.
2Center of Pharmaceutical Outcomes Research, Naresuan University, Phitsanulok, Thailand.
BMC Rheumatol. 2017 Nov 28;1:5. doi: 10.1186/s41927-017-0003-6. eCollection 2017.
To determine the prevalence of depression among Japanese people with rheumatoid arthritis (RA) and explore the relationships between depression and an array of variables.
Nation-wide, cross-sectional online survey ( = 500) of people with RA including the Patient Health Questionnaire (PHQ-9) to measure the presence and severity of depressive symptoms were performed.
While only 5% of the population studied had been officially diagnosed with depression, 35% had PHQ-9 scores indicating depression was present. People with RA are more likely to experience depression if they are younger, have greater functional impairment, or whose treatment regimen includes pain medications not biologic agents.
It is a potential risk of under-diagnosis and under-reporting of depression in Japanese people with RA. People with RA are more likely to experience depression if they are younger, have greater functional impairment, or whose treatment regimen includes pain medications without biologic drugs.
确定日本类风湿关节炎(RA)患者中抑郁症的患病率,并探讨抑郁症与一系列变量之间的关系。
对RA患者进行了一项全国性的横断面在线调查(n = 500),包括使用患者健康问卷(PHQ-9)来测量抑郁症状的存在情况和严重程度。
虽然所研究人群中只有5%被正式诊断为抑郁症,但35%的人PHQ-9得分表明存在抑郁症。如果RA患者更年轻、功能损害更大,或者其治疗方案包括非生物制剂的止痛药物,则他们更有可能患抑郁症。
在日本RA患者中,抑郁症存在诊断不足和报告不足的潜在风险。如果RA患者更年轻、功能损害更大,或者其治疗方案包括不含生物药物的止痛药物,则他们更有可能患抑郁症。